Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Clinical trial NCT02587650 · TERMINATED

Trial details

NCT number: NCT02587650
Sponsor: University of California, San Francisco
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

ALK Fusion Protein Expression BRAF wt Allele Invasive Skin Melanoma MET Fusion Gene Positive NRAS wt Allele NTRK1 Fusion Positive NTRK2 Fusion Positive NTRK3 Fusion Positive RET Fusion Positive ROS1 Fusion Positive Stage III Cutaneous Melanoma Stage IIIA Cutaneous Melanoma

Start date: 2015-03-26
Primary completion: 2018-07-12
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.